U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Hemiretinal vein occlusion

MedGen UID:
1703639
•Concept ID:
C1735356
•
Pathologic Function
HPO: HP:0020167

Definition

A variant of central retinal vein occlusions that involves the superior or inferior half of the retina. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVHemiretinal vein occlusion

Professional guidelines

PubMed

Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.
Kymes SM, Oden NL, VanVeldhuisen PC, Scott IU, Ip MS, Blodi BA, King J; SCORE2 Investigator Group
JAMA Ophthalmol 2023 Jun 1;141(6):554-561. doi: 10.1001/jamaophthalmol.2023.1463. PMID: 37166820Free PMC Article
Management of macular edema secondary to central retinal vein occlusion: an evidence-based.
Aref AA, Scott IU
Adv Ther 2011 Jan;28(1):40-50. Epub 2010 Dec 9 doi: 10.1007/s12325-010-0088-4. PMID: 21153510
Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion.
Gregori NZ, Rattan GH, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, Murray TG
Retina 2009 Jul-Aug;29(7):913-25. doi: 10.1097/IAE.0b013e3181aa8dfe. PMID: 19584649

Recent clinical studies

Etiology

SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Investigator Group
Ophthalmology 2023 Oct;130(10):1066-1072. Epub 2023 May 21 doi: 10.1016/j.ophtha.2023.05.023. PMID: 37220815Free PMC Article
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.
Kymes SM, Oden NL, VanVeldhuisen PC, Scott IU, Ip MS, Blodi BA, King J; SCORE2 Investigator Group
JAMA Ophthalmol 2023 Jun 1;141(6):554-561. doi: 10.1001/jamaophthalmol.2023.1463. PMID: 37166820Free PMC Article
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group
JAMA Ophthalmol 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. PMID: 35323843Free PMC Article
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group
JAMA Ophthalmol 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. PMID: 34709363Free PMC Article
Association of glaucoma with risk of retinal vein occlusion: A meta-analysis.
Yin X, Li J, Zhang B, Lu P
Acta Ophthalmol 2019 Nov;97(7):652-659. Epub 2019 May 24 doi: 10.1111/aos.14141. PMID: 31125174

Diagnosis

SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Investigator Group
Ophthalmology 2023 Oct;130(10):1066-1072. Epub 2023 May 21 doi: 10.1016/j.ophtha.2023.05.023. PMID: 37220815Free PMC Article
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.
Kymes SM, Oden NL, VanVeldhuisen PC, Scott IU, Ip MS, Blodi BA, King J; SCORE2 Investigator Group
JAMA Ophthalmol 2023 Jun 1;141(6):554-561. doi: 10.1001/jamaophthalmol.2023.1463. PMID: 37166820Free PMC Article
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group
JAMA Ophthalmol 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. PMID: 35323843Free PMC Article
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group
JAMA Ophthalmol 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. PMID: 34709363Free PMC Article
Hemiretinal vein occlusion in Wegener's granulomatosis.
Venkatesh P, Chawla R, Tewari HK
Eur J Ophthalmol 2003 Oct;13(8):722-5. doi: 10.1177/112067210301300811. PMID: 14620179

Therapy

SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Investigator Group
Ophthalmology 2023 Oct;130(10):1066-1072. Epub 2023 May 21 doi: 10.1016/j.ophtha.2023.05.023. PMID: 37220815Free PMC Article
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.
Kymes SM, Oden NL, VanVeldhuisen PC, Scott IU, Ip MS, Blodi BA, King J; SCORE2 Investigator Group
JAMA Ophthalmol 2023 Jun 1;141(6):554-561. doi: 10.1001/jamaophthalmol.2023.1463. PMID: 37166820Free PMC Article
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group
JAMA Ophthalmol 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. PMID: 35323843Free PMC Article
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group
JAMA Ophthalmol 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. PMID: 34709363Free PMC Article
Association of glaucoma with risk of retinal vein occlusion: A meta-analysis.
Yin X, Li J, Zhang B, Lu P
Acta Ophthalmol 2019 Nov;97(7):652-659. Epub 2019 May 24 doi: 10.1111/aos.14141. PMID: 31125174

Prognosis

OCT Grading System of Macular Infarction Predicts Vision in Participants With Central Retinal or Hemiretinal Vein Occlusion: A Secondary Analysis of SCORE2.
Au A, Ip M, Blodi BA, Scott IU, Oden NL, Van Veldhuisen PC, Sarraf D
Am J Ophthalmol 2023 Dec;256:55-62. Epub 2023 Aug 5 doi: 10.1016/j.ajo.2023.07.028. PMID: 37544495Free PMC Article
SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Investigator Group
Graefes Arch Clin Exp Ophthalmol 2022 May;260(5):1491-1500. Epub 2021 Nov 29 doi: 10.1007/s00417-021-05494-5. PMID: 34842984Free PMC Article
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group
JAMA Ophthalmol 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. PMID: 34709363Free PMC Article
Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.
Khurana RN, Oden NL, VanVeldhuisen PC, Scott IU, Blodi BA, Ip MS; SCORE2 Investigator Group
Graefes Arch Clin Exp Ophthalmol 2021 Jul;259(7):1839-1851. Epub 2021 Jan 7 doi: 10.1007/s00417-020-05018-7. PMID: 33415354Free PMC Article
Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion.
Gregori NZ, Rattan GH, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, Murray TG
Retina 2009 Jul-Aug;29(7):913-25. doi: 10.1097/IAE.0b013e3181aa8dfe. PMID: 19584649

Clinical prediction guides

OCT Grading System of Macular Infarction Predicts Vision in Participants With Central Retinal or Hemiretinal Vein Occlusion: A Secondary Analysis of SCORE2.
Au A, Ip M, Blodi BA, Scott IU, Oden NL, Van Veldhuisen PC, Sarraf D
Am J Ophthalmol 2023 Dec;256:55-62. Epub 2023 Aug 5 doi: 10.1016/j.ajo.2023.07.028. PMID: 37544495Free PMC Article
SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Investigator Group
Ophthalmology 2023 Oct;130(10):1066-1072. Epub 2023 May 21 doi: 10.1016/j.ophtha.2023.05.023. PMID: 37220815Free PMC Article
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.
Kymes SM, Oden NL, VanVeldhuisen PC, Scott IU, Ip MS, Blodi BA, King J; SCORE2 Investigator Group
JAMA Ophthalmol 2023 Jun 1;141(6):554-561. doi: 10.1001/jamaophthalmol.2023.1463. PMID: 37166820Free PMC Article
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group
JAMA Ophthalmol 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. PMID: 35323843Free PMC Article
Association of glaucoma with risk of retinal vein occlusion: A meta-analysis.
Yin X, Li J, Zhang B, Lu P
Acta Ophthalmol 2019 Nov;97(7):652-659. Epub 2019 May 24 doi: 10.1111/aos.14141. PMID: 31125174

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...